Complex chromosome rearrangements (CCRs) are unusual structural chromosome alterations found in humans, and to date only a few have been characterized molecularly. New mechanisms, such as chromothripsis, have been proposed to explain the presence of the CCRs in cancer cells and in patients with congenital disorders and/or mental retardation. The aim of the present study was the molecular characterization of a constitutional CCR in a girl with multiple congenital disorders and intellectual disability in order to determine the genotype-phenotype relation and to clarify whether the CCR could have been caused by chromosomal catastrophic events. The present CCR was characterized by G-banding, high-resolution CGH, multiplex ligation-dependent probe amplification and subtelomeric 2q-FISH analyses. Preliminary results indicate that the de novo CCR is unbalanced showing a 2q37.3 deletion and 2q34q37.2 partial trisomy. Our patient shows some of the typical traits and intellectual disability described in patients with 2q37 deletion and also in carriers of 2q34q37.2 partial trisomy; thus, the clinical disorders could be explained by additional effects of both chromosome alterations (deletions and duplications). A posterior, sequential FISH study using BAC probes revealed the unexpected presence of at least 17 different reorganizations affecting 2q34q37.2, suggesting the existence of chromosome instability in this region. The present CCR is the first case described in the literature of heterogeneity of unbalanced CCRs affecting a small region of 2q, indicating that the mechanisms involved in constitutional chromosome rearrangement may be more complex than previously thought.

1.
Alfred MA, Sanford RO, Thomas NS, Barrow MA, Wilson LC, et al: Molecular analysis of 20 patients with 2q37.3 monosomy: definition of minimum deletion intervals for key phenotypes. J Med Genet 41:433-339 (2004).
2.
Baptista J, Mercer C, Prigmore E, Gribble SM, Carter NP, et al: Breakpoint mapping and array CGH in translocations: comparison of a phenotypically normal and an abnormal cohort. Am J Hum Genet 82:927-936 (2008).
3.
Batanian JR, Eswara MS: De novo apparently balanced complex chromosome rearrangement (CCR) involving chromosomes 4, 18, and 21 in a girl with mental retardation: report and review. Am J Med Genet 78:44-51 (1998).
4.
Beck CR, Carvalho CM, Banser L, Gambin T, Stubbolo D, et al: Complex genomic rearrangements at the PLP1 locus include triplication and quadruplication. PLoS Genet 11: e1005050 (2015).
5.
Brand H, Pillalamarri V, Collins RL, Eggert S, O'Dushlaine C, et al: Cryptic and complex chromosomal aberrations in early-onset neuropsychiatric disorders. Am J Hum Genet 95:454-461 (2014).
6.
Cetin Z, Yakut S, Clark OA, Mihci E, Berker S, Luleci G: A 5q12.1-5q12.3 microdeletion in a case with a balanced exceptional complex chromosomal rearrangement. Gene 516:176-180 (2013).
7.
Chaabouni M, Le Merrer M, Raoul O, Prieur M, de Blois MC, et al: Molecular cytogenetic analysis of five 2q37 deletions: refining the brachydactyly candidate region. Eur J Med Genet 49:255-263 (2006).
8.
Chiang C, Jacobsen JC, Ernst C, Hanscom C, Heilbut A, et al: Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet 44:390-397 (2012).
9.
Cuscó I, del Campo M, Vilardell M, González E, Gener B, et al: Array-CGH in patients with Kabuki-like phenotype: identification of two patients with complex rearrangements including 2q37 deletions and no other recurrent aberration. BMC Med Genet 9:27 (2008).
10.
Falk RE, Casas KA: Chromosome 2q37 deletion: clinical and molecular aspects. Am J Med Genet C Semin Med Genet 145C:357-371 (2007).
11.
Fan YS, Zhang Y, Speevak M, Farrell S, Jung JH, Siu VM: Detection of submicroscopic aberrations in patients with unexplained mental retardation by fluorescence in situ hybridization using multiple subtelomeric probes. Genet Med 3:416-421 (2001).
12.
Felder B, Radlwimmer B, Benner A, Mincheva A, Tödt G, et al: FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome. Am J Med Genet A 149A:952-959 (2009).
13.
Gamba BF, Richieri-Costa A, Costa S, Rosenberg C, Ribeiro-Bicudo LA: Chromothripsis with at least 12 breaks at 1p36.33-p35.3 in a boy with multiple congenital anomalies. Mol Genet Genomics 290:2213-2216 (2015).
14.
Genesio R, Ronga V, Castelluccio P, Fioretti G, Mormile A, et al: Pure 16q21q22.1 deletion in a complex rearrangement possibly caused by a chromothripsis event. Mol Cytogenet 6:29 (2013).
15.
Gu H, Jiang JH, Li JY, Zhang YN, Dong XS, et al: Familial cri-du-chat/5p deletion syndrome resulted from rare maternal complex chromosomal rearrangements (CCRs) and/or possible chromosome 5p chromothripsis. PLoS One 8:e76985 (2013).
16.
Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, et al: Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 88:306-316 (2011).
17.
Hemmat M, Yang X, Chan P, McGough RA, Ross L, et al: Characterization of a complex chromosomal rearrangement using chromosome, FISH, and microarray assays in a girl with multiple congenital abnormalities and developmental delay. Mol Cytogenet 29:50 (2014).
18.
Hermsen MA, Tijssen M, Acero IH, Meijer GA, Ylstra B, Toral JF: High resolution microarray CGH and MLPA analysis for improved genotype/phenotype evaluation of two childhood genetic disorder cases: ring chromosome 19 and partial duplication 2q. Eur J Med Genet 48:310-318 (2005).
19.
Houge G, Liehr T, Schoumans J, Ness GO, Solland K, et al: Ten years follow up of a boy with a complex chromosomal rearrangement: going from a >5 to 15-breakpoint CCR. Am J Med Genet A 118A:235-240 (2003).
20.
ISCN 2013. An International System for Human Cytogenetic Nomenclature; in Shaffer LG, Slovak ML, Campbell LJ (eds) (Karger, Basel 2013).
21.
Jones MJ, Jallepalli PV: Chromothripsis: chromosomes in crisis. Dev Cell 23:908-917 (2012).
22.
Kloosterman WP, Cuppen E: Chromothripsis in congenital disorders and cancer: similarities and differences. Curr Opin Cell Biol 25:341-348 (2013).
23.
Kloosterman WP, Guryev V, van Roosmalen M, Duran KJ, de Bruijn E, et al: Chromothripsis as a mechanism driving complex de novo structural rearrangements in the germline. Hum Mol Genet 20:1916-1924 (2011).
24.
Kloosterman WP, Tavakoli-Yaraki M, van Roosmalen MJ, van Binsbergen E, Renkens I, et al: Constitutional chromothripsis rearrangements involve clustered double-stranded DNA breaks and nonhomologous repair mechanisms. Cell Rep 1:648-655 (2012).
25.
Lee NC, Chen M, Ma GC, Lee DJ, Wang TJ, et al: Complex rearrangements between chromosomes 6, 10, and 11 with multiple deletions at breakpoints. Am J Med Genet A 152:2327-2334 (2010).
26.
Leroy C, Landais E, Briault S, David A, Tassy O, et al: The 2q37-deletion syndrome: an update of the clinical spectrum including overweight, brachydactyly and behavioural features in 14 new patients. Eur J Hum Genet 21:602-612 (2013).
27.
Liu P, Erez A, Nagamani SC, Dhar SU, Kołodziejska KE, et al: Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell 146:889-903 (2011).
28.
López-Expósito I, Bafalliu JA, Santos M, Fuster C, Puche-Mira A, Guillén-Navarro E: Intrachromosomal partial triplication of chromosome 13 secondary to a paternal duplication with mild phenotypic effect. Am J Med Genet A 146A:1190-1194 (2008).
29.
Macera MJ, Sobrino A, Levy B, Jobanputra V, Aggarwal V, et al: Prenatal diagnosis of chromothripsis, with nine breaks characterized by karyotyping, FISH, microarray and whole-genome sequencing. Prenat Diagn 35:299-301 (2015).
30.
Macina RA, Negorev DG, Spais C, Ruthig LA, Hu XL, Riethman HC: Sequence organization of the human chromosome 2q telomere. Hum Mol Genet 3:1847-1853 (1994).
31.
Madan K: Balanced complex chromosome rearrangements: reproductive aspects. A review. Am J Med Genet A 158:947-963 (2012).
32.
Nazaryan L, Stefanou EG, Hansen C, Kosyakova N, Bak M, et al: The strength of combined cytogenetic and mate-pair sequencing techniques illustrated by a germline chromothripsis rearrangement involving FOXP2. Eur J Hum Genet 22:338-343 (2014).
33.
Nguyen MH, Morel F, Pennamen P, Parent P, Douet-Guilbert N, et al: Balanced complex chromosome rearrangement in male infertility: case report and literature review. Andrologia 47:178-185 (2015).
34.
Nonaka T, Ooki I, Enomoto T, Takakuwa K: Complex chromosomal rearrangements in couples affected by recurrent spontaneous abortion. Int J Gynaecol Obstet 128:36-39 (2015).
35.
Pai GS, Thomas GH, Mahoney W, Migeon BR: Complex chromosome rearrangements. Report of a new case and literature review. Clin Genet 18:436-444 (1980).
36.
Pellestor F, Anahory T, Lefort G, Puechberty J, Liehr T, et al: Complex chromosomal rearrangements: origin and meiotic behavior. Hum Reprod Update 17:476-494 (2011).
37.
Pellestor F, Gatinois V, Puechberty J, Geneviève D, Lefort G: Chromothripsis: potential origin in gametogenesis and preimplantation cell divisions. A review. Fertil Steril 102:1785-1796 (2014).
38.
Plaisancié J, Kleinfinger P, Cances C, Bazin A, Julia S, et al: Constitutional chromoanasynthesis: description of a rare chromosomal event in a patient. Eur J Med Genet 57:567-570 (2014).
39.
Poot M, Haaf T: Mechanisms of origin, phenotypic effects and diagnostic implications of complex chromosome rearrangements. Mol Syndromol 6:110-134 (2015).
40.
Quinlan AR, Hall IM: Characterizing complex structural variation in germline and somatic genomes. Trends Genet 28:43-53 (2012).
41.
Righolt C, Mai S: Shattered and stitched chromosomes - chromothripsis and chromoanasynthesis - manifestations of a new chromosome crisis? Genes Chromosomes Cancer 51:975-981 (2012).
42.
Roukos V, Burman B, Misteli T: The cellular etiology of chromosome translocations. Curr Opin Cell Biol 25:357-364 (2013).
43.
Slavotinek AM, Boles D, Lacbawan F: A female infant with duplication of chromosome 2q33 to 2q37.3. Clin Dysmorphol 12:251-256 (2003).
44.
Sorzano CO, Pascual-Montano A, Sánchez de Diego A, Martínez-A C, van Wely KH: Chromothripsis: breakage-fusion-bridge over and over again. Cell Cycle 12:2016-2023 (2013).
45.
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40 (2011).
46.
Vera-Carbonell A, López-Expósito I, Bafalliu JA, Ballesta-Martínez M, Glóver G, et al: Molecular characterization of a new patient with a non-recurrent inv dup del 2q and review of the mechanisms for this rearrangement. Am J Med Genet A 152A:2670-2680 (2010).
47.
Waldron D: Genome stability: chromothripsis and micronucleus formation. Nat Rev Genet 16:376-377 (2015).
48.
Wang JC, Fisker T, Sahoo T: Constitutional chromothripsis involving chromosome 19 in a child with subtle dysmorphic features. Am J Med Genet A 167:910-913 (2015).
49.
Wang T, Mao J, Liu MJ, Choy KW, Li HB, et al: A patient with five chromosomal rearrangements and a 2q31.1 microdeletion. Clin Chim Acta 430:129-133 (2014).
50.
Zeman MK, Cimprich KA: Causes and consequences of replication stress. Nat Cell Biol 16:2-9 (2014).
51.
Zhang CZ, Leibowitz ML, Pellman D: Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes Dev 27:2513-2530 (2013).
52.
Zhang CZ, Spektor A, Cornils H, Francis JM, Jackson EK, et al: Chromothripsis from DNA damage in micronuclei. Nature 522:179-184 (2015).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.